All Posts

AACR2026: Treatment-induced senescence in mRCC: implications for single-cell biology and therapeutic intervention

AACR2026 : STX-1, a first-in-class ADC targeting DPP4 protein, acts as an anticancer and senolytic treatment

Presentations highlight therapy-induced senescence as a new therapeutic opportunity and reinforce the potential of STX-1 as a differentiated approach for solid tumors Lille and Villejuif, France, April 16, 2026 – StarkAge Therapeutics, a biotechnology company pioneering first-in-class senolytic antibody-drug conjugates (ADC) for age-related diseases with an initial focus on oncology, today announced that it will present two posters at the AACR Annual Meeting 2026. These data

Cell - Hallmarks of liver cancer: Therapeutic implications

The collaboration will inform patient selection for treatment with STX-1, a first-in-class senolytic ADC directed against dipeptidyl-peptidase 4 (DPP4/CD26) as it progresses toward IND-enabling studies. Lille, France, January 27th, 2025 – StarkAge Therapeutics, a biotechnology company developing first-in-class senolytic antibody-drug conjugates (ADC) in age-related diseases, with an initial focus on oncology, today announced a research collaboration with Gustave Roussy, Europ

Cell Genomics - Cellular senescence in human liver under normal aging and cancer

• Reinforcing StarkAge’s transition toward IND-enabling and early clinical development for STX-1 • Florence Lhospice, PharmD, PhD, brings ADC and CMC expertise as well as a strategic leadership to advance Starkage pipeline • Eric Angevin, MD, PhD, seasoned early-development oncologist, adds rare, direct clinical expertise in DPP4-targeted therapies Lille, France – December 4, 2025 – StarkAge Therapeutics, a biotechnology company developing first-in-class senolytic antibody-dr

Journal of Hepatology - Cellular senescence in liver diseases : From molecular drivers to therapeutic targeting

Lille, the 20th of May 2024. StarkAge Therapeutics, a French biotechnology company, announces a €1.2 million fundraising round conducted with biotech focused business angels. The company, founded in 2018, specializes in the targeting of cellular senescence in the context of age-related pathologies, especially cancer. Currently, cancers are mainly treated with radiotherapy, chemotherapy and/or targeted therapy. These therapies can lead to the emergence of senescent cells withi